T-cell Lymphoma Clinical Trial
Official title:
Prospective Collection of Data in Patients With T-cell Lymphomas Distributed in the Five Distinct Macro Regions of Brazil
The designed study follows up on the previous one by the international T-cell project (Bellei
et al,, 2012) and its purpose is to verify whether a prospective collection of data would
permit access to more accurate information permitting a better definition of prognosis and
investigation of more adequate treatment strategies for these neoplasms.
The analysis of patients distributed in all five macro regions of the country and a
comparison among them will provide a real picture of the disease in Brazil, limiting the bias
probably found in the previous projects.
Patients with diagnosis histologically confirmed T-cell or NK-cell lymphoma will be registered in the study, despite of their planned treatment. Registration will be made on-line on a key restricted accessible web-database after obtaining the informed consent dated and signed by the patient. Every registered patient has as well to undergo a central histopathology review by a panel of experts. The referring pathologist will collect and review the patological material sent by the participating centers, without knowing the clinical outcome of the patient. Validated cases have to be supplied of information regarding treatment procedures and follow up updating for at least 5 years. The primary endpoint is the overall survival and other endpoints such as event free survival; progression free survival, complete and partial response rates. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00959686 -
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04712864 -
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01941680 -
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
|
||
Recruiting |
NCT05075460 -
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
|
Phase 3 | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT02017613 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT01854112 -
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
|
N/A | |
Completed |
NCT01553786 -
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
|
Phase 2 | |
Completed |
NCT00542919 -
A Study for Patients With Non-Hodgkin's Lymphomas
|
Phase 2 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Active, not recruiting |
NCT03952078 -
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT05387226 -
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT02424045 -
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT01871675 -
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT00893516 -
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
|
Phase 2 | |
Completed |
NCT01902225 -
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
Recruiting |
NCT04264078 -
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
|
Early Phase 1 | |
Completed |
NCT00001582 -
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
|